ViiV’s Rukobia wins EU authorisation to treat multidrug-resistant HIV
Rukobia is a first-in-class HIV attachment inhibitor
Read More
Tag: ViiV Healthcare
US green light for long-acting HIV regimen Cabenuva
Cabenuva consists of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine
Read More
ViiV Healthcare continues HIV care partnership with Chelsea and Westminster Hospital
Partnership aims to transform HIV patient care with digital services
Read More
EU approval for ViiV’s Tivicay for children living with HIV
First dispersible tablet formulation of Tivicay now available for children in the EU
Read More
EU nod for first long-acting HIV injectable treatment
Rekambys plus Vocabria authorised to treat HIV-1 infections in adults who are virologically suppressed
Read More
ViiV’s cabotegravir scores breakthrough designation for HIV prevention
Designation is based on results from phase IIb/III HPTN 083 trial
Read More
ViiV’s long-acting HIV drug beats standard of care in prevention study
Study was ended early after drug hit primary endpoint
Read More
ViiV posts positive long-term data for two-drug HIV regimen Dovato
Dovato demonstrated non-inferior efficacy compared to TAF-based regimens
Read More
ViiV’s two-drug HIV regimen demonstrates long-term efficacy
Two-drug regimen continues to offer non-inferior efficacy compared to a three-drug regimen
Read More
HIV transmissions fall by 71%
The UK is “well on its way towards our ambition of zero HIV transmissions by 2030.”
Read More
ViiV’s long-acting two-drug HIV regimen hits targets
A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.
Read More
ViiV, Havas Lynx chart toppers at PM Society Awards
ViiV Healthcare has come out on top at this year’s PM Society Awards, an annual competition designed to recognise creativity, impact and innovation across pharmaceutical and healthcare advertising and communications.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
